Antares Pharma Inc

Antares Pharma — Investor Presentation (September 2019)

22 slides from Antares Pharma's investor presentation, Sep 10, 2019

  1. Slide 1: Antares Pharma Investors' Update September 2019

    Antares Pharma Investors’ Update September 2019 EX 99.1

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements within the meaning of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those des

  3. Slide 3: Antares Pharma Overview

    Antares Pharma is an innovative leader in self-administered injection technology Five products utilizing FDA-approved Antares devices were commercialized in the past five years; three in 2018 alone XYOSTED® (testosterone enanthate) Makena® (hydroxyprogesterone) Generic EpiPen® (epinephrine) All are

  4. Slide 4: Continued dramatic shift toward growth in product revenue

    Continued dramatic shift toward growth in product revenue Q219 - $20.6M in product revenue – an 86% increase compared to the same period one year ago Commercialized proprietary products: XYOSTED® and OTREXUP®: $9.0M Partnered products: Teva EpiPen Teva Sumatriptan AMAG Makena® Needle Free Antares Ph

  5. Slide 5: Antares Pharma Proprietary Commercial Products

    Antares Pharma Proprietary Commercial Products September 2019

  6. Slide 6: An innovative way to deliver testosterone replacement therapy

    An innovative way to deliver testosterone (T) replacement therapy 98.5% of phase-3 study XYOSTED® patients achieved testosterone levels in the normal, physiologic range A narrow peak-to-trough ratio of 1.8 means T levels stay steady T Levels maintained for as long as the patient stays on therapy* St

  7. Slide 7: Ctrough Stable For Weeks

    Ctrough Stable For 52 Weeks 6 12 18 26 38 52 Week 1, pre-dose Mean Ctrough (ng/dL) over 52 week “003” study Green lines represent the defined range of 300 – 1100 ng/dL ………….. Baseline QST-13-003 treatment regimen demonstrated a mean steady state concentration of testosterone of 553.3 ± 127.3 ng/dL a

  8. Slide 8: Multiple Channels Directed at Key Targets

    Trial Experience Multiple Channels Directed at Key Targets Multi-channeling campaign targets physicians and patients through digital, social, enduring, and live platforms that drive awareness, prescription generation, and prescription fulfillment Access program further aids prescription fulfillment

  9. Slide 9: XYOSTED Growth Since Launch

    More than 20,000* XYOSTED® TRx’s to date written by ~2,800 different physicians More than 10,000 patients prescribed XYOSTED® since launch XYOSTED® Growth Since Launch

  10. Slide 10: Broad Utilization Across all TRT Specialties

    Commercial Experience Broad Utilization Across all TRT Specialties

  11. Slide 11: Antares Commercial Products: OTREXUP and generic sumatriptan

    Commercial Experience Antares Commercial Products OTREXUP® (methotrexate) for injection and generic sumatriptan generated combined revenue of $29 million in 2018 Q2 2019 combined revenue was $7.3 million 2019 year-to-date combined revenue - $14.9 million

  12. Slide 12: Antares Pharma Partnered Commercial Products

    Antares Pharma Partnered Commercial Products September 2019

  13. Slide 13: Teva's Generic EpiPen

    Commercial Experience Teva’s Generic EpiPen Teva’s generic EpiPen® was approved by FDA as therapeutically equivalent to Mylan’s EpiPen® and is fully substitutable at the pharmacy Antares receives cost plus margin on all devices sold to Teva plus mid-to-high, single-digit royalties on in-market sales

  14. Slide 14: Generic EpiPen Monthly Prescription Trends

    Commercial Experience Generic EpiPen® Monthly Prescription Trends

  15. Slide 15: Makena hydroxyprogesterone caproate injection

    Commercial Experience Makena® hydroxyprogesterone caproate injection Makena® is to used to reduce the risk of pre-term birth in certain at-risk women Provides patients with efficient, discreet, and user-friendly administration AMAG/Antares collaboration began in 2014 Antares receives cost plus produ

  16. Slide 16: Antares Pharma Development Pipeline

    Antares Pharma Development Pipeline September 2019

  17. Slide 17: Antares Pharma Pipeline

    Commercial Experience Antares Pharma Pipeline Product Preclinical Phase 1 Phase 2 Phase 3 Marketed Antares Proprietary and Partnered Products Teriparatide (Teva) Exenatide (Teva) ATRS-1701 Neurology (Antares) Methotrexate for Ectopic Pregnancy (Antares) Orphan Status Undisclosed Rescue Pen (Pfizer)

  18. Slide 18: Antares Pharma Q2 2019 Financial Results

    Antares Pharma Q2 2019 Financial Results September 2019

  19. Slide 19: Antares Pharma Q2 and YTD 2019

    Commercial Experience Antares Pharma Q2 and YTD 2019 Three Months Ended June 30 Increase Six Months Ended June 30 Increase 2019 2018 (Decrease) 2019 2018 (Decrease) Total Revenue $ 28,433 $ 14,162 101% $ 51,719 $ 26,865 93% Cost of Revenue 12,441 6,960 79% 23,387 14,146 65% Gross Profit 15,992 7,202

  20. Slide 20: 5-year Growth and 2019 Projection

    +17% vs. 2017 +57-73% vs. 2018* 5-year Growth and 2019 Projection Projected CAGR of 31.7% * Percent increase based on revised 2019 guidance +72% vs. 2014 +14% vs. 2015

  21. Slide 21: Antares Pharma: 5 Potential Catalysts

    Continued XYOSTED® prescription growth and adoption Continued generic EpiPen® and EpiPen® Jr. prescription growth and adoption Continued contribution from the Makena® subcutaneous hydroxyprogesterone auto-injector Potential FDA approval and launch of Teva’s generic teriparatide (Forteo®) for patient

  22. Slide 22: Thank you / Questions

    antares pharma Thank you Questions making medicines better fool

Antares Pharma — Investor Presentation (September 2019) on 6ix